Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.10 | 1.50 | 0.02% |
| CAC 40 | 8,436.24 | 43.63 | -0.51% |
| DAX 40 | 25,465.25 | 352.64 | -1.37% |
| Dow JONES (US) | 52,925.15 | 130.76 | -0.25% |
| FTSE 100 | 10,665.88 | 14.11 | 0.13% |
| HKSE | 24,057.24 | 560.35 | 2.38% |
| NASDAQ | 25,818.69 | 302.47 | -1.16% |
| Nikkei 225 | 67,776.74 | 480.22 | -0.70% |
| NZX 50 Index | 13,675.48 | 87.31 | -0.63% |
| S&P 500 | 7,503.85 | 33.58 | -0.45% |
| S&P/ASX 200 | 8,748.10 | 10.50 | 0.12% |
| SSE Composite Index | 4,011.05 | 20.82 | 0.52% |